ATI-9242
- Generic Name
- ATI-9242
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Radiation: [18F]Fallypride Imaging
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02824666
- Locations
- 🇺🇸
Indiana Clinical Research Center, IU Health University Hospital, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath